Orei Health Secures EU Funding under Component IIa
We are proud to announce that Orei Health has achieved another significant milestone – our project has been recommended for EU funding under Component IIa of the Eastern Poland European Funds (FEPW) program, coordinated by the Polish Agency for Enterprise Development (PARP).
This recognition validates the potential of our innovation and will accelerate the development of Orei One – a breakthrough device for painless, at-home blood collection.
Why this matters
The Component IIa program aims to strengthen the growth and competitiveness of young companies in Eastern Poland, helping them bring new products and services to market.
In the latest call for proposals:
74 applications were submitted, requesting over 43 million PLN in funding,
35 projects were recommended for support,
with a total allocation of more than 20 million PLN.
Orei Health among the selected projects
Orei Health is honored to be part of this group. Our proprietary device, Orei One, enables self-blood collection without the need for a clinic visit or medical personnel.
The technology has been designed for:
patients with chronic conditions,
telemedicine users,
health-conscious individuals,
and clinical trial applications.
Our mission is to make diagnostics more accessible while reducing pain, stress, and discomfort for patients – all while ensuring laboratory-quality samples.
Summary
With the support of the European Funds and PARP, Orei Health can accelerate its mission: shaping the future of blood collection – painless, needle-free, and accessible to everyone.
We thank our partners, mentors, and collaborators for their continuous support. This milestone is not just ours – it’s a shared step forward in building better healthcare for tomorrow. 💙
